Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

Looking for a natural alternative to GLP-1 drugs? Integrative medicine physician Dr. Taz Bhatia has shared three foods that ...

NASM's Understanding Weight Loss Medications offers fitness and wellness professionals comprehensive, evidence-based research, along with exercise, nutrition, and behavioral strategies to support ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.